Greenstein A J, Wisnivesky J P, Litle V R
Department of General Surgery, Mount Sinai School of Medicine, New York, NY 10029-6574, USA.
Dis Esophagus. 2008;21(8):673-8. doi: 10.1111/j.1442-2050.2008.00832.x. Epub 2008 May 2.
Surgical resection is the current standard treatment for patients with early stage cancer of the esophagus. In a subset of these patients, comorbidities prohibit the operative risks of a potentially curative esophagectomy. Such patients may be candidates for local endoscopic treatment. We sought to look at a large cohort of patients with clinically localized esophagus cancer to determine whether high-risk patients survive significantly longer after endoscopic therapy than those who receive no local treatment. T0 or T1, N0 esophageal cancer (EC) patients who did not receive surgery or radiation were identified from the Surveillance, Epidemiology, and End Results cancer registry (1998-2003). The patients were assigned into two groups: local endoscopic therapy (excisional biopsy, photodynamic, local destruction, thermal laser, polypectomy, electrocautery, or cryoablation) versus no endoscopic therapy. Differences in survival were calculated using the Kaplan-Meier method, and a multivariate Cox regression analysis adjusting for potential confounders was used to analyze the effect of local therapy on survival. The study cohort included 166 T0 or T1, N0 EC patients. (75% male; 50% >70 years old). Tumors were adenocarcinoma (60%), squamous cell carcinoma (24%), and other (16%). The 4-year disease-specific survival rate was 84% for patients receiving local therapy compared with 64% for patients receiving no therapy (P < 0.01). On multivariate analysis, patients receiving local therapy had a significantly lower hazard of EC-related death (P = 0.04). There was no difference in survival curves for deaths secondary to causes other than EC. Local endoscopic therapy significantly prolonged survival in high-risk patients with clinical T0 or T1, N0 EC and is a reasonable alternative for those patients who are not candidates for potentially curative esophagectomy.
手术切除是早期食管癌患者目前的标准治疗方法。在这些患者的一部分中,合并症使潜在治愈性食管切除术的手术风险过高。这类患者可能适合局部内镜治疗。我们试图观察一大群临床局限性食管癌患者,以确定高危患者接受内镜治疗后的生存期是否明显长于未接受局部治疗的患者。从监测、流行病学和最终结果癌症登记处(1998 - 2003年)中识别出未接受手术或放疗的T0或T1、N0期食管癌(EC)患者。患者被分为两组:局部内镜治疗(切除活检、光动力治疗、局部破坏、热激光、息肉切除术、电灼或冷冻消融)与未接受内镜治疗。使用Kaplan - Meier方法计算生存率差异,并使用多变量Cox回归分析调整潜在混杂因素,以分析局部治疗对生存的影响。研究队列包括166例T0或T1、N0期EC患者。(75%为男性;50%年龄>70岁)。肿瘤类型为腺癌(60%)、鳞状细胞癌(24%)和其他(16%)。接受局部治疗的患者4年疾病特异性生存率为84%,而未接受治疗的患者为64%(P < 0.01)。多变量分析显示,接受局部治疗的患者EC相关死亡风险显著降低(P = 0.04)。除EC外其他原因导致的死亡的生存曲线无差异。局部内镜治疗显著延长了临床T0或T1、N0期EC高危患者的生存期,对于那些不适合进行潜在治愈性食管切除术的患者来说是一种合理的替代方法。